Matthew Phillip Sinnreich - 31 Oct 2022 Form 4/A - Amendment Insider Report for Organicell Regenerative Medicine, Inc. (ZEOX)

Reporting relationship: President and Acting CEO, Director
Issuer ticker: ZEOX
Reported as of: 31 Oct 2022
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 03 Nov 2022, 17:01:38 UTC
Original report date: 01 Nov 2022
Prior SEC filing: 17 Oct 2022
Source filing: View source filing
Reporting owner signature: /s/ Dale S. Bergman as attorney-in-fact for Matthew Sinnreich

Key filing fact

Matthew Phillip Sinnreich filed Form 4/A - Amendment for Organicell Regenerative Medicine, Inc. (ZEOX) on 03 Nov 2022.

Key facts

This page summarizes Matthew Phillip Sinnreich's Form 4/A - Amendment filing for Organicell Regenerative Medicine, Inc. (ZEOX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Nov 2022, 17:01.

Change

Previous filing in this sequence was filed on 17 Oct 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCEL transaction

Common Stock, $0.001 par value

Other

Transaction value
Shares: -6,976,000
Change %: -100%
Price
Shares after: 0
Date: 31 Oct 2022
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On October 31, 2022, the Reporting Person relinquished his ownership interest in Retrograde Investments, LLC, which held the shares of common stock reported hereunder. As a result, the Reporting Person no longer exercises any voting or and dispositive power over such shares.